The right key opinion leader or KOL identification — with whom medical science liaisons (MSL) communicate and engage — can transform the effectiveness of the medical affairs and field medical teams. The MSL-KOL relationship can be crucial to successful patient outcomes.
“Medical Affairs teams are critically seeking better ways to communicate their value,” says Tim Mikhelashvili, CEO & Co-Founder, Amedea Pharma. “The focus of their value proposition is shifting towards patient outcomes and the patient journey through all of their activities,” Mikhelashvili explains. “As a result, the MSL (medical science liaison) value is now best expressed not only in the data they collect and communicate, but primarily in the context of the data they are able to capture and translate clinically.”
Knowing whom to approach and how to connect with them in this ever-changing landscape is central to ensuring that the team can elevate new treatments and improve patient outcomes in a real-world setting. Seeking quality engagements — those that transform the treatment paradigm — and not just quantity of engagements, will be the yardstick by which medical affairs teams are measured in the future.
Register now to learn about moving the MSL-KOL relationships from perfunctory to powerful. Join the featured speakers in reviewing the importance of KOL Identification and management and learn how to leverage the right technology and tools to create a quality engagement.
Erick Borg, PharmD, Customer Success Manager, Medical Affairs, Anju
Erick recently joined the Customer Success team at Anju, helping teams to understand and take full advantage of the medical affairs suite of products. Erick has over 10 years of direct experience in medical affairs at biotechnology and pharmaceutical companies, having held both medical information and medical communications roles. Erick holds a Doctor of Pharmacy degree.Message Presenter
Steve Anzuini, Senior Solutions Engineer, Medical Affairs, Anju
Steve Anzuini has 10 plus years of experience within the medical affairs field. Currently, he serves as Anju’s Sr. Solutions Engineer and Subject-Matter Expert within their KOL Engagement and Publications Management offerings. Steve is committed to providing advanced software solutions to the pharmaceutical, biotechnology and medical device industries, helping his clients engage efficiently in real-time across the globe. Steve holds a Bachelor of Science in Technical Communication from James Madison.Message Presenter
John Coritz, Senior Director, Customer Success, Anju
John Coritz is Senior Director for Customer Success at Anju. He has over 23 years’ experience in clinical trial operations, country and site identification/feasibility, digital technology and strategic clinical planning. John is a firm believer in bringing all actionable business intelligence sources together to make educated business decisions.Message Presenter
Who Should Attend?
- Medical affairs organizational leaders
- Medical science liaisons
- Field medical team leads
- Anyone interested in leveraging technology to move medical affairs’ value from output to impact
What You Will Learn
- Understand the shifting landscape of medical science liaison-key opinion leader (MSL-KOL) engagement
- Appreciate the difference between quantity of engagements vs. quality engagements
- Review available practices, tools and technologies to enhance quality MSL-KOL engagements
Anju provides adaptive technologies for clinical trials, medical affairs, and data with world-class customer support. Leveraging AI and data driven analytics, our leading suite of solutions with data and application integration capabilities serves the worldwide pharmaceutical, biotech and contract research Life Sciences markets.